EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.

BRUSSELS/LONDON (Reuters) - EU antitrust regulators have asked pharma rivals and customers for feedback in four business ...

CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...

A summary of current health news details EU regulators probing Novo Nordisk's $16.5 billion Catalent takeover, Amgen's ...

Catalent (NYSE:CTLT – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...